文献速递泌尿男性生殖肿瘤

局部晚期膀胱癌大分割放疗:BC2001与BCON试验个体患者数据荟萃分析

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
PubMed 文献 · Lancet Oncol · 2021-01-01

结论认为55 Gy/20次在侵袭性局部区域控制方面非劣效且优效,应作为膀胱保留的标准治疗。

要点

  • 55 Gy/20次/4周方案在侵袭性局部区域控制上非劣效于64 Gy/32次,且复发风险更低。
  • 两种方案的晚期膀胱或直肠毒性相似,非劣效性成立。
  • 55 Gy/20次/4周应作为局部晚期膀胱癌膀胱保留的标准治疗。

核心结论

  • 推荐将55 Gy/20次/4周作为局部晚期膀胱癌膀胱保留的标准治疗。

研究设计与样本

  • 研究为个体患者数据荟萃分析,纳入BC2001(NCT00024349)和BCON(NCT00033436)两项英国多中心随机对照III期试验。
  • 纳入年龄≥18岁、局部晚期膀胱癌(T1G3或T2-T4,N0M0)且已知分次方案的患者,共782例(BC2001 456例,BCON 326例)。
  • 376例(48%)接受64 Gy/32次,406例(52%)接受55 Gy/20次;中位随访120个月(IQR 99-159)。
  • 采用一阶段个体患者数据荟萃分析模型,校正试验差异、中心内相关性、随机治疗、基线变量不平衡及预后因素混杂。

临床怎么用

  • 对于局部晚期膀胱癌拟行膀胱保留放疗的患者,可优先选择55 Gy/20次/4周的大分割方案。
  • 该方案在局部控制和晚期毒性方面不劣于常规分割,且局部控制可能更优,可作为标准治疗选项。

局限性

  • 分次方案并非随机分配,而是根据各中心标准实践选择,可能存在选择偏倚。
  • 研究仅纳入两项英国随机试验的数据,外推性需谨慎。
  • 原文未报告其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 32 fractions over 6·5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term outcomes of these schedules in several cohort studies and case series suggest that response, survival, and toxicity are similar, but no direct comparison has been published. The present study aimed to assess the non-inferiority of 55 Gy in 20 fractions to 64 Gy in 32 fractions in terms of invasive locoregional control and late toxicity in patients with locally advanced bladder cancer. METHODS: We did a meta-analysis of individual patient data from patients (age ≥18 years) with locally advanced bladder cancer (T1G3 [high-grade non-muscle invasive] or T2-T4, N0M0) enrolled in two multicentre, randomised, controlled, phase 3 trials done in the UK: BC2001 (NCT00024349; assessing addition of chemotherapy to radiotherapy) and BCON (NCT00033436; assessing hypoxia-modifying therapy combined with radiotherapy). In each trial, the fractionation schedule was chosen according to local standard practice. Co-primary endpoints were invasive locoregional control (non-inferiority margin hazard ratio [HR]=1·25); and late bladder or rectum toxicity, assessed with the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic tool (non-inferiority margin for absolute risk difference [RD]=10%). If non-inferiority was met for invasive locoregional control, superiority could be considered if the 95% CI for the treatment effect excluded the null effect (HR=1). One-stage individual patient data meta-analysis models for the time-to-event and binary outcomes were used, accounting for trial differences, within-centre correlation, randomised treatment received, baseline variable imbalances, and potential confounding from relevant prognostic factors. FINDINGS: 782 patients with known fractionation schedules (456 from the BC2001 trial and 326 from the BCON trial; 376 (48%) received 64 Gy in 32 fractions and 406 (52%) received 55 Gy in 20 fractions) were included in our meta-analysis. Median follow-up was 120 months (IQR 99-159). Patients who received 55 Gy in 20 fractions had a lower risk of invasive locoregional recurrence than those who received 64 Gy in 32 fractions (adjusted HR 0·71 [95% CI 0·52-0·96]). Both schedules had similar toxicity profiles (adjusted RD -3·37% [95% CI -11·85 to 5·10]). INTERPRETATION: A hypofractionated schedule of 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fractions with regard to both invasive locoregional control and toxicity, and is superior with regard to invasive locoregional control. 55 Gy in 20 fractions should be adopted as a standard of care for bladder preservation in patients with locally advanced bladder cancer. FUNDING: Cancer Research UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021. PMID: 33539743. doi:10.1016/S1470-2045(20)30607-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。